InMode Anticipates Strong Q1 2026 Financial Results and Conference Call Announcement InMode Ltd. expects its Q1 2026 revenue to be between $81.5 million and $81.7 million. The company will hold a conference call to discuss results on May 6, 2026.

InMode Anticipates Strong Q1 2026 Financial Results and Conference Call Announcement #Israel #financial_results #Yokneam #InMode #Q1_2026

Lumenis Launches triLIFT 2.0: A Breakthrough in Muscle Stimulation for Aesthetics Lumenis has unveiled triLIFT 2.0, a revolutionary muscle stimulation platform for enhanced facial and body aesthetics, catering to the rising demand for non-surgical solutions.

Lumenis Launches triLIFT 2.0: A Breakthrough in Muscle Stimulation for Aesthetics #Israel #Yokneam #Lumenis #triLIFT #muscle_stimulation

InMode Launches New Share Repurchase Initiative to Strengthen Shareholder Value and Maintain Market Position InMode Ltd. has unveiled a share repurchase program targeting up to 10% of its outstanding shares, demonstrating confidence in its financial health and market position.

InMode Launches New Share Repurchase Initiative to Strengthen Shareholder Value and Maintain Market Position #Israel #share_repurchase #Financial_Strategy #Yokneam #InMode

InMode Concludes Transaction Committee Review, Focuses on Growth Strategies InMode Ltd. has completed its independent transaction committee review, finding no proposals aligned with its best interests, while focusing on growth strategies.

InMode Concludes Transaction Committee Review, Focuses on Growth Strategies #Israel #Yokneam #Medical_Technologies #InMode #Nasdaq_INMD

InMode Releases Fourth Quarter and Full Year 2025 Financial Performance Results with GAAP Revenue Trends InMode Ltd. unveils its financial outcomes for Q4 and FY 2025, highlighting revenue shifts and strategic outlook for growth.

InMode Releases Fourth Quarter and Full Year 2025 Financial Performance Results with GAAP Revenue Trends #Israel #financial_results #medical_technology #Yokneam #InMode

InMode Ltd. Addresses Recent Acquisition Rumors and Strategic Review Process InMode Ltd. publicly addresses acquisition rumors and outlines its ongoing strategic review process, reassuring investors about future prospects.

InMode Ltd. Addresses Recent Acquisition Rumors and Strategic Review Process #Israel #Steel_Partners #Yokneam #InMode #INMD

Trisol Medical's Innovative Valve Replacement System Shows Promising Results in U.S. Study Trisol Medical's transcatheter valve replacement system demonstrates significant safety and efficacy in severe tricuspid regurgitation patients, offering hope for innovative heart therapies.

Trisol Medical's Innovative Valve Replacement System Shows Promising Results in U.S. Study #USA #medical_technology #Yokneam #Tricuspid_Valve #Trisol_Medical

Trisol Medical Reports Success in Early Study of Transcatheter Tricuspid Valve Replacement System Trisol Medical has shared promising results from a U.S. study on its innovative transcatheter tricuspid valve replacement system, demonstrating both safety and effectiveness.

Trisol Medical Reports Success in Early Study of Transcatheter Tricuspid Valve Replacement System #USA #Yokneam #Heart_Treatment #Trisol_Medical #Transcatheter_Valve

InMode's Q3 2025 Financial Results: A Detailed Overview of Revenue and Growth Prospects InMode has released its financial results for Q3 2025, reporting a revenue of $93.2 million, a drop from last year but a solid gross margin of 78%.

InMode's Q3 2025 Financial Results: A Detailed Overview of Revenue and Growth Prospects #NASDAQ #Israel #financial_results #Yokneam #InMode

InMode Ltd. to Showcase Innovative Medical Technologies at Investment Conferences InMode Ltd. is set to participate in various investor conferences this November, aiming to highlight its cutting-edge medical technologies in healthcare.

InMode Ltd. to Showcase Innovative Medical Technologies at Investment Conferences #Israel #Investor_Conferences #Yokneam #InMode_Ltd #Medical_Technologies

InMode Announces Impressive Second Quarter 2025 Financial Outcomes with $95.6 Million Revenue InMode Ltd. reported a strong second quarter for 2025, achieving $95.6 million in revenue and maintaining impressive 80% gross margins. This sets a positive tone for future growth.

InMode Announces Impressive Second Quarter 2025 Financial Outcomes with $95.6 Million Revenue #Israel #financial_results #Q2_2025 #Yokneam #InMode_Ltd.

NVIDIA baut Mega-Campus im Norden Israels – Datenzentrum soll Hightech-Herz des Landes stärken Der Chipriese NVIDIA will bei Yokne’am massiv expandieren – mit einem neuen Supercomputer-Zentrum und Tausenden Jobs. Das Projekt könnte Israels Norden zum nächsten Hightech-Magneten machen.

NVIDIA baut Mega-Campus im Norden Israels – Datenzentrum soll Hightech-Herz des Landes stärken
Der Chipriese NVIDIA will bei Yokne’am massiv expandieren – mit einem neuen Sup...
#Nvidia #Israel #Yokneam #Forschung #Supercomputer #Mellanox
haolam.de/artikel/Isra...

InMode Achieves Health Canada Certification for IgniteRF Platform with QuantumRF Technology InMode Ltd. proudly announces the Health Canada certification of IgniteRF, integrating advanced QuantumRF technology for innovative, minimally invasive treatments.

InMode Achieves Health Canada Certification for IgniteRF Platform with QuantumRF Technology #Canada #Yokneam #InMode #QuantumRF #IgniteRF

InMode's Participation Announced for Major Investor Conferences in 2025 InMode Ltd. has unveiled its upcoming participation in significant investor conferences including BNP Aesthetics Day and Jefferies Healthcare Conference in 2025.

InMode's Participation Announced for Major Investor Conferences in 2025 #Israel #Investor_Conferences #medical_technology #Yokneam #InMode_Ltd

InMode Ltd. Announces First Quarter 2025 Financial Results Amid Market Challenges InMode Ltd. reports a revenue dip in Q1 2025 with a focus on innovation and international performance. The company remains resilient amid economic pressures.

InMode Ltd. Announces First Quarter 2025 Financial Results Amid Market Challenges #Israel #financial_results #medical_technology #Yokneam #InMode_Ltd

Butterfly Medical Appoints Dr. James Ulchaker to Boost BPH Treatment Innovations Butterfly Medical has appointed Dr. James Ulchaker as Chief Medical Officer to enhance its treatment for Benign Prostatic Hyperplasia (BPH) and gain FDA approval.

Butterfly Medical Appoints Dr. James Ulchaker to Boost BPH Treatment Innovations #Israel #Yokneam #BPH_Treatment #Butterfly_Medical #Dr._Ulchaker

Cytora Unveils Promising Phase 1/2a Trial Results for Innovative Stem Cell Therapy in Diabetic Foot Ulcers Cytora announces significant success in a Phase 1/2a trial using hOMSCs for treating diabetic foot ulcers, hinting at a revolutionary approach in stem cell therapy.

Cytora Unveils Promising Phase 1/2a Trial Results for Innovative Stem Cell Therapy in Diabetic Foot Ulcers #Israel #Diabetic_Foot_Ulcers #Yokneam #Cytora #Stem_Cell_Treatment

TRAC Incident Report: Knife-Wielding Assailant Shot Dead After Ramming His Vehicle onto a Bus Stop in Yokneam Illit, Lower Galilee, Northern Israel - 24 March 2025 Knife-Wielding Assailant Shot Dead After Ramming His Vehicle onto a Bus Stop in Yokneam Illit, Lower Galilee, Northern Israel

Knife-Wielding Assailant Shot Dead After Ramming His Vehicle onto a #Bus Stop in #Yokneam Illit, Lower Galilee, Northern #Israel
trackingterrorism.org/chatter/knif...

🚨 BREAKING: Terror attack near Yokne’am, Israel leaves soldier seriously injured 💥. The assailant rammed his car into people at a bus stop before stabbing the 20-year-old soldier, stealing his rifle, and fatally shooting an elderly man 🚨. #Israel #TerrorAttack #Yokneam #Security

Terroranschlag bei Yokne am: Ein Toter und ein Verletzter bei Schussattacke Ein Mann wurde bei einer Schussattacke an der HaTishbi-Kreuzung nahe Yokne’am getötet, ein weiterer verletzt. Der mutmaßliche Attentäter wurde von Sicherheitskräften neutralisiert.

Israel: Terroranschlag bei Yokne am: Ein Toter und ein Verletzter bei Schussattacke

Ein Mann wurde bei einer Schussattacke an der ...
#Terroranschlag #Israel #Yokneam #Schussattacke #MagenDavidAdom #Polizei #Verletzte #Notfallmedizin
haolam.de/artikel/Isra...

InMode's Response to DOMA Perpetual: Clarifying Capital Strategies and Management Practices InMode Ltd. addresses the concerns raised by DOMA Perpetual regarding its capital allocation and management practices, reaffirming its commitment to shareholder value.

InMode's Response to DOMA Perpetual: Clarifying Capital Strategies and Management Practices #Israel #Yokneam #Medical_Technologies #InMode #DOMA

InMode's Participation in Upcoming Investor Conferences Highlighting Innovative Medical Technologies InMode Ltd. announces its participation in key investor conferences in March to showcase innovative medical technologies and engage with stakeholders.

InMode's Participation in Upcoming Investor Conferences Highlighting Innovative Medical Technologies #Israel #Investor_Conferences #Yokneam #Medical_Technologies #InMode

InMode Reports Financial Results for Q4 and Full Year 2024 with New Share Repurchase Program Announced InMode Ltd. shares its financial performance for Q4 and FY 2024, announcing a share repurchase initiative as capital returns continue amidst industry challenges.

InMode Reports Financial Results for Q4 and Full Year 2024 with New Share Repurchase Program Announced #Israel #financial_results #share_repurchase #Yokneam #InMode_Ltd

ElastiMed Strengthens Medical Expertise with Dr. Steve Elias Appointment ElastiMed Ltd. has appointed Dr. Steve Elias to its Medical Advisory Board, enhancing its commitment to innovative healthcare solutions for vascular diseases.

ElastiMed Strengthens Medical Expertise with Dr. Steve Elias Appointment #Israel #ElastiMed #Steve_Elias #Medical_Advisory_Board #Yokneam